TrialEuropean journal of clinical pharmacology2016

Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.

Mari Fihlman et al.PubMed ↗Publisher ↗

No numbers read from the abstract.